During the past decade, CH Dunkerque conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 5 clinical trials were completed, i.e. on average, 9.8% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 2 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Dunkerque" #1 sponsor was "University Hospital, Lille" with 21 trials, followed by "Intergroupe Francophone du Myelome" with 8 trials sponsored, "The Lymphoma Academic Research Organisation" with 8 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 5 trials sponsored and "Acute Leukemia French Association" with 5 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Dunkerque" #1 collaborator was "Ministry of Health, France" with 8 trials as a collaborator, "Intergroupe Francophone du Myelome" with 3 trials as a collaborator, "Région Nord-Pas de Calais, France" with 3 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator and "Janssen, LP" with 2 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "CH Dunkerque" are "Multiple Myeloma" (13 trials), "Acute Myeloid Leukemia" (3 trials), "Myeloma" (3 trials), "Acute Myeloid Leukemia (AML)" (2 trials) and "Alcoholic Hepatitis" (2 trials). Many other conditions were trialed in "CH Dunkerque" in a lesser frequency.

Most popular intervention types in "CH Dunkerque" are "Drug" (50 trials), "Other" (9 trials), "Procedure" (9 trials), "Device" (6 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Rituximab" (6 trials), "Lenalidomide" (4 trials), "Dexamethasone" (3 trials) and "Idelalisib" (3 trials). Other intervention names were less common.

The vast majority of trials in "CH Dunkerque" are 82 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "CH Dunkerque". 1 are not yet recruiting, 19 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in CH Dunkerque, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in CH Dunkerque, 0 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 19 trials that are defined as “Not Applicable".